WestView Capital Partners, a Boston-based private equity firm, has made a growth investment in Dark Horse Consulting Group, a cell and gene therapy (CGT) consultancy company.
DHC uses its team of consultants to help clients meet their strategic and operational goals, from corporate strategy development to technical implementation and regulatory road mapping. The company offers its services to therapeutic developers, investors, and tools, technology and service providers in the CGT category. Greg Thomas, general partner at Westview, will join DHC’s board of directors.
“Our investment in Dark Horse reflects WestView’s commitment to partnering with leading life science service companies led by passionate and experienced entrepeneurs,” says Thomas. “We are thrilled to partner with them and look forward to helping Dark Horse grow and expand its service offering.”
WestView was represented by Latham & Watkins LLP. DHC was represented by Fenwick and West LLP.